Search Within

Alexander Edward Drilon

  1. "Early Drug Development Service"
Formats
  1. Meeting Abstract (62)
  2. Journal Article (47)
  3. Research Letter (1)
  4. Review (1)
Groups
  1. Department of Medicine (111)
  2. Early Drug Development Service (111)
  3. Solid Tumor Oncology Division (111)
  4. Thoracic Oncology (111)
  5. Department of Pathology and Laboratory Medicine (61)
  6. GSK Faculty (55)

More Groups

People
  1. David Hyman (78)
  2. Alison Schram (46)
  3. Marc Ladanyi (37)
  4. Jaclyn Hechtman (26)
  5. Ryma Benayed (25)
  6. Michael Berger (24)

More People

Years
  1. 2025 (1)
  2. 2024 (1)
  3. 2023 (6)
  4. 2022 (8)
  5. 2021 (15)
  6. 2020 (18)

More Years

Publications
  1. Journal of Clinical Oncology (26)
  2. Annals of Oncology (15)
  3. Cancer Research (10)
  4. Clinical Cancer Research (8)
  5. Journal of Thoracic Oncology (7)
  6. Cancer Discovery (6)

More Publications

Publishers
  1. American Society of Clinical Oncology (32)
  2. American Association for Cancer Research (25)
  3. Oxford University Press (16)
  4. Elsevier Inc. (9)
  5. Nature Publishing Group (8)
  6. Massachusetts Medical Society (3)

More Publishers

Results (111)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II basket study of the oral TRK inhibitor LOXO-101 in adult subjects with NTRK fusion-positive tumors
    Meeting Abstract

    Drilon, A.; Hong, D.; Deeken, J.; Smith, S.; Reynolds, M.; Cruickshank, S.; Deegan, M.; Ku, N.; Hyman, D.
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program
    Journal Article

    Drilon, A.; Eaton, A. A.; Schindler, K.; Gounder, M. M.; Spriggs, D. R.; Harris, P.; Ivy, S. P.; Iasonos, A.; Lacouture, M. E.; Hyman, D. M.
    Cancer (2016)

    Fulltext@MSK | Save
  • What hides behind the MASC: Clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)
    Journal Article

    Drilon, A.; Li, G.; Dogan, S.; Gounder, M.; Shen, R.; Arcila, M.; Wang, L.; Hyman, D. M.; Hechtman, J.; Wei, G.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Toxicity attribution in phase I trials: Evaluating the effect of dose on the frequency of related and unrelated toxicities
    Journal Article

    Eaton, A.; Iasonos, A.; Gounder, M. M.; Pamer, E. G.; Drilon, A.; Vulih, D.; Smith, G. L.; Ivy, S. P.; Spriggs, D. R.; Hyman, D. M.
    Clinical Cancer Research (2016)

    Fulltext@MSK | Save
  • Clinically adoption of MSK-IMPACT, a hybridization capture-based next generation sequencing assay, for the assessment of lung adenocarcinomas
    Meeting Abstract

    Arcila, M. E.; Zehir, A.; Yu, H.; Drilon, A.; Li, B. T.; Riely, G. J.; Rekhtman, N.; Lin, O.; Hyman, D.; Berger, M.; more...
    Journal of Thoracic Oncology (2015)

    Fulltext@MSK | Save
  • Ado-trastuzumab emtansine for HER2 amplified or HER2 overexpressed cancers: A phase II "basket" trial
    Meeting Abstract

    Li, B. T.; Zauderer, M.; Chaft, J.; Drilon, A.; Eng, J.; Sima, C.; Makker, V.; Iyer, G.; Janjigian, Y.; Hyman, D.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Lurbinectedin (PM01183) in combination with paclitaxel (P) in patients (pts) with advanced solid tumors
    Meeting Abstract

    Garralda, E.; Stathis, A.; Drilon, A.; Boni, V.; Hyman, D.; Calvo, E.; Griguolo, G.; Makker, V.; Doger, B.; Canziani, L.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • Phase I trial of the HSP-90 inhibitor PU-H71
    Meeting Abstract

    Gerecitano, J. F.; Modi, S.; Rampal, R.; Drilon, A. E.; Fury, M. G.; Gounder, M. M.; Harding, J. J.; Hyman, D. M.; Varghese, A. M.; Voss, M. H.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Physician toxicity attribution in phase I trials: Evaluating the effect of dose on the frequency of 11,909 toxicities
    Meeting Abstract

    Eaton, A.; Iasonos, A.; Gounder, M. M.; Pamer, E.; Drilon, A. E.; Vulih, D.; Smith, G. L.; Ivy, P.; Spriggs, D. R.; Hyman, D. M.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Dermatologic toxicities of 3,517 solid tumor patients on phase I clinical trials of the National Institutes of Health Cancer Therapy Evaluation Program (CTEP)
    Meeting Abstract

    Drilon, A. E.; Eaton, A.; Schindler, K.; Gounder, M. M.; Smith, G. L.; Vulih, D.; Harris, P. J.; Spriggs, D. R.; Ivy, P.; Iasonos, A.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save